Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Esophageal Squamous Cell Carcinoma(ALTER1102)
NCT02649361 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Esophageal Squamous Cell Carcinoma(ALTER1102)
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2016
- Completion date
- July 23, 2018
- Enrollment
- 164 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.